Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Teva Pharmaceuticals announced FDA approval for WELTRUZA, a once-monthly subcutaneous injectable for schizophrenia. The approval follows positive Phase 3 trial results showing symptom improvement and safety. Teva will host an investor call on October 9, 2026. WELTRUZA will be available in three strengths and targets a significant unmet need in schizophrenia treatment.
How this was made
The 30-second read
Why it matters
The approval expands Teva's long‑acting injectable franchise and could boost its neuroscience revenue outlook.
Market read
A novel schizophrenia treatment approved by the FDA, likely to affect Teva's stock and the broader psychiatric‑drug market.
What to watch
Reimbursement negotiations and insurance coverage could delay revenue realization.
Background
Teva announced FDA approval of its once‑monthly olanzapine injectable, the first of its kind, and scheduled an investor call for Oct 9.
Ticker impact
FDA approval of WELTRUZA™ (once‑monthly olanzapine injection) gives Teva a new revenue stream in schizophrenia treatment.
potential upside as investors price in future sales and market share gains.
First‑of‑its‑kind once‑monthly subcutaneous LAI for olanzapine; large schizophrenia market; no loading dose or monitoring required, likely improves adherence and drives uptake.
Market effects
Strengthens the psychiatric‑drugs segment and may pressure competitors lacking a monthly injectable option.
U.S. market focus with potential rollout in Europe pending EMA approval.
Adds a novel schizophrenia therapy to the global pharma pipeline, could influence analyst forecasts for mental‑health drugmakers.
Counterpoint
If adoption is slower than expected, the product may not offset declining oral sales, limiting upside.
Key entities
- companyTeva Pharmaceuticals
U.S. affiliate of Teva Pharmaceutical Industries Ltd., ticker TEVA.
- productWELTRUZA™
Olanzapine extended‑release injectable suspension for schizophrenia.
